文献速递妇科生殖医学

新型低剂量铜镍钛宫内节育器:36个月II期数据

Efficacy, Safety, and Tolerability of a New Low-Dose Copper and Nitinol Intrauterine Device: Phase 2 Data to 36 Months.
PubMed 文献 · Obstet Gynecol · 2020-01-01

本研究在美国12个中心纳入286名经产与未产女性,评估新型低剂量铜(175 mm²)镍钛框架宫内节育器的疗效、安全性与耐受性。36个月观察中Pearl指数为0.46(95%CI 0.06-1.67),放置成功率99.0%,无子宫穿孔,10.6%因不良事件早期取出。

要点

  • 36个月Pearl指数0.46,仅2例妊娠,显示高避孕效果。
  • 放置成功率99.0%,脱落率1.8%,无子宫穿孔,严重不良事件均与研究无关。
  • 第一年内10.6%因不良事件取出,其中8.1%因出血、疼痛或两者兼有。

核心结论

  • 新型低剂量铜镍钛宫内节育器在II期试验中显示高疗效和安全性,值得进一步开展III期临床研究。

研究设计与样本

  • II期、多中心(美国12个站点)研究,纳入286名符合铜基IUD标准纳入与排除标准的经产和未产女性。
  • 研究为期1年并延长2年,共观察36个月,评估妊娠、放置成功、不良事件、 discontinuation率及出血模式。

主要发现

  • 共286名女性提供5,640个可评估妊娠的周期,平均年龄27.1岁,未产女性占60.8%。
  • 36个月观察期间发现2例妊娠,Pearl指数0.46(95%CI 0.06-1.67)。
  • 发生10例严重不良事件,均与研究无关;放置成功283例(99.0%)。
  • 中位(范围)继续使用时间为2.7年(0-3.4);脱落5例(1.8%),子宫穿孔0例,盆腔炎1例报告。
  • 第一年内30名女性(10.6%)因不良事件提前取出,其中23名(8.1%)因出血、疼痛或两者兼有;107名(37.8%)完成36个月使用。

临床怎么用

  • 该装置在经产和未产女性中均显示高放置成功率和低妊娠率,可考虑作为铜基IUD的候选。
  • 需关注第一年内因出血或疼痛导致的取出风险,咨询时应告知患者相关 discontinuation 率。

局限性

  • 本研究为II期试验,样本量有限(286名),结论需III期试验进一步验证。
  • 研究由商业机构资助(Sebela Pharmaceuticals, Inc.)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess in parous and nulliparous women, the efficacy, safety, and tolerability of a new, low-dose copper (175 mm) intrauterine contraceptive with a flexible nitinol frame provided in a preloaded applicator. METHODS: Institutional review boards at 12 U.S. sites approved this commercially funded project. Patients met standard inclusion and exclusion criteria for a copper-based intrauterine device (IUD), generally consistent with the Centers for Disease Control and Prevention's U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. Intrauterine device placement occurred at any day in the eligible patient's menstrual cycle after assuring she was not pregnant. The primary outcome measure assessed efficacy (measured by the Pearl Index) in this 1-year study with a 2-year extension. Secondary outcomes included placement success, ease of placement, safety as measured by adverse events, and tolerability assessed by discontinuation rate and bleeding and spotting patterns. RESULTS: A total of 286 women provided 5,640 cycles evaluable for pregnancy. Patients averaged 27.1 years of age. Nulliparous women represented 60.8% of the patients. Over 36 months of observation, we identified two pregnancies (Pearl Index 0.46 [95% CI 0.06-1.67]) and 10 serious adverse events; none were study-related. Successful placement occurred in 283 participants (99.0%). Median (range) continuation times were 2.7 years (0-3.4). We identified five expulsions (1.8%), zero uterine perforations, and one report of pelvic inflammatory disease. Adverse events prompted 30 women (10.6%) to discontinue early in the first year of use with 23 (8.1%) discontinuing for issues of bleeding, pain, or both. Altogether, 107 (37.8%) completed 36 months of device use. Mean bleeding days per cycle decreased from 7.6 in cycle 1 to 5.2 in cycle 13. CONCLUSION: The novel, low-dose copper and nitinol IUD demonstrated high efficacy and safety in this phase 2 U.S. Food and Drug Administration trial and warrants further expanded study in a phase 3 clinical trial. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02446821. FUNDING SOURCE: Sebela Pharmaceuticals, Inc.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Turok DK, Nelson AL, Dart C, et al. Efficacy, Safety, and Tolerability of a New Low-Dose Copper and Nitinol Intrauterine Device: Phase 2 Data to 36 Months. Obstet Gynecol. 2020. PMID: 32168217. doi:10.1097/AOG.0000000000003756

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。